Ultragenyx Pharmaceutical Inc. (RARE) Presents at Bank of America Global Healthcare Conference 2025 Transcript

Ultragenyx Pharmaceutical's Chief Medical Officer, Eric Crombez, confirmed at the Bank of America Global Healthcare Conference that its Osteogenesis Imperfecta (OI) program did not clear its second interim analysis. A full study readout for this key pipeline asset, considered a significant value driver, is now anticipated around December or January, signaling a potential setback for the company's development timeline.

Analysis

Ultragenyx Pharmaceutical Inc. (RARE) has confirmed a significant clinical development hurdle for one of its primary pipeline assets. At the Bank of America Global Healthcare Conference, Chief Medical Officer Eric Crombez stated that the company's Osteogenesis Imperfecta (OI) program "did not clear our second interim analysis." This outcome necessitates waiting for the full study readout, introducing a material delay and substantial binary risk for what the company considers a "big value driver." Management has guided that these top-line results will be disclosed externally "around the end of the year," specifically in December or January. The failure at the interim stage casts considerable uncertainty over a crucial component of the company's valuation narrative, a sentiment reflected in the strongly negative sentiment score (-0.7 for RARE) associated with this update.

Key Decisions for Investors

• Investors should prepare for heightened stock volatility and view the upcoming full OI study readout in December/January as a major binary event.
• Given the failure at the interim analysis, which negatively impacts the perceived probability of a successful outcome, it is prudent to reassess risk exposure to RARE ahead of the final data release.
• Pay closer attention to progress in Ultragenyx's other key programs, particularly the Angelman Syndrome asset, as their success becomes more critical to supporting the company's valuation following this setback.